A recent trial involving 156 participants with advanced gastric or gastro-oesophageal junction cancer, resistant to previous treatments, showed positive outcomes with Satri-cel. This cell therapy, administered up to 3 times alongside immune cell depletion, demonstrated efficacy in individuals positive for CLDN18.2. The control group received standard therapies like nivolumab, paclitaxel, or rivoceranib.
Read more from nature.com
